New approach aims to fight cancer while protecting patients from harsh side effects

This study is testing whether adding an anti-inflammatory drug called infliximab to standard immunotherapy helps people with advanced melanoma. The goal is to see if this combination can better control the cancer while also reducing the severe digestive side effects that sometimes come with immunotherapy. About 36 adults with metastatic melanoma who haven't had certain prior treatments will receive either the combination or standard therapy plus a placebo.